NYU Langone Health’s Department of Neurology is presenting more than 80 talks and posters at the AAN 2026 annual meeting in Chicago, including phase 3 X-TOLE2 results for azetukalner in focal onset seizures and a qualitative study on barriers faced by patients with disabilities in outpatient neurology settings.
NYU Langone Health says its Department of Neurology is presenting more than 80 talks and posters at the 2026 annual meeting of the American Academy of Neurology in Chicago, which runs from April 18 to April 22.
Among the presentations is phase 3 X-TOLE2 data on azetukalner in focal onset seizures, which will be presented by Jacqueline A. French. NYU Langone and Xenon Pharmaceuticals said the study met its primary endpoint with statistically significant seizure reduction in both dose groups.
The meeting roster also includes a qualitative study led by Mihir Kakara on how patients with disabilities navigate outpatient healthcare environments and the barriers they face. According to the NYU Langone summary, the study included 21 patients who used mobility assistive equipment and found obstacles at every stage of a visit, from the parking lot to exit.
The presentations add to a busy AAN week for NYU Langone neurologists as the field gathers for one of its largest annual conferences. The organization has not yet indicated whether additional meeting findings will be highlighted in the days ahead.
Revision note
Initial automated publication.